Source-grounded facts extracted from METLIFE INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
METLIFE INC reported the quarter ended March 31, 2026 results: revenue $14,315, net income $1,140, EPS $1.74 per share.
“otherwise noted. Page 2 of 25 First Quarter 2026 Summary ($ in millions, except per share data) Three Months Ended March 31, 2026 2025 Change Premiums, fees and other revenues $ 14,315 $ 13,639 5% Net investment income 5,355 4,885 10% Net investment gains (losses) (670) (387) Net derivative gains (losses) 74 432 Total revenues $ 19,074 $ 18,569 Adjusted”
METLIFE INC incurred senior notes of $1,000,000,000 aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 5.850% Fixed-to-Fixed Reset Rate maturing 2056.
“On February 26, 2026, MetLife, Inc. (the “Company”) issued $1,000,000,000 aggregate principal amount of its 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056 (the “Debentures”).”
METLIFE INC: Certificate of Elimination filed to remove Series G Preferred Stock from the Amended and Restated Certificate of Incorporation (effective 2025-10-14).
“On October 14, 2025, MetLife, Inc. (the “Company”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware to eliminate its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G (“the Series G Preferred Stock”), all shares of which the Company previously redeemed, repurchased or otherwise reacquired.”
METLIFE INC incurred senior notes of ¥87,840,000,000 at 2.14%, 2.46%, 2.59%, 2.83%, 3.29%, 3.62% maturing June 17, 2032, June 17, 2035, June 17, 2037, June 17, 2040, June 17, 2045, June 17, 2055.
“On June 17, 2025, MetLife, Inc., a Delaware corporation (the “Company”), entered into a Note Purchase Agreement with the purchasers named therein (the “Purchase Agreement”) in connection with the offer and sale in a private placement of an aggregate principal amount of ¥87,840,000,000 of the Company’s yen-denominated senior notes.”
David L. Herzog resigned as Director at METLIFE INC.
“On March 27, 2025, David L. Herzog, a director of MetLife, Inc. (the “Company”), notified the Company’s Board of Directors (the “Board”) of his decision to resign from the Board, effective May 1, 2025, and not to stand for re-election at the Company’s 2025 annual meeting of shareholders.”
Christian Mumenthaler was elected as director at METLIFE INC.
“elected Christian Mumenthaler a director of the Company and appointed Mr. Mumenthaler to its Finance and Risk Committee and its Investment Committee, effective May 1, 2025.”
Toby Srihiran Brown was appointed as interim Chief Accounting Officer at METLIFE INC.
“appointed Toby Srihiran Brown, Executive Vice President and Global Head of Reinsurance of the Company, as the Company’s interim Chief Accounting Officer, to be effective as of March 15, 2025”
Tamara L. Schock resigned as Executive Vice President and Chief Accounting Officer at METLIFE INC.
“Tamara L. Schock, notified the Company of her intent to resign as Executive Vice President and Chief Accounting Officer of the Company.”
Tamara L. Schock resigned as Executive Vice President and Chief Accounting Officer at METLIFE INC.
“On January 7, 2025, Tamara L. Schock, Executive Vice President and Chief Accounting Officer of MetLife, Inc. (the “Company”), informed the Company that she would resign from her position to pursue another opportunity.”
METLIFE INC incurred senior notes of ¥15,500,000,000 aggregate principal amount of its 2.195% Senior Notes due 2044 with The Bank of New York Mellon Trust Company, N.A. at 2.195% maturing 2044.
“¥15,500,000,000 aggregate principal amount of its 2.195% Senior Notes due 2044 (the “2044 Senior Notes”)”
METLIFE INC incurred senior notes of ¥11,200,000,000 aggregate principal amount of its 1.953% Senior Notes due 2039 with The Bank of New York Mellon Trust Company, N.A. at 1.953% maturing 2039.
“¥11,200,000,000 aggregate principal amount of its 1.953% Senior Notes due 2039 (the “2039 Senior Notes”)”
METLIFE INC incurred senior notes of ¥16,700,000,000 aggregate principal amount of its 1.670% Senior Notes due 2034 with The Bank of New York Mellon Trust Company, N.A. at 1.670% maturing 2034.
“¥16,700,000,000 aggregate principal amount of its 1.670% Senior Notes due 2034 (the “2034 Senior Notes”)”
METLIFE INC incurred senior notes of ¥23,100,000,000 aggregate principal amount of its 1.415% Senior Notes due 2031 with The Bank of New York Mellon Trust Company, N.A. at 1.415% maturing 2031.
“¥23,100,000,000 aggregate principal amount of its 1.415% Senior Notes due 2031 (the “2031 Senior Notes”)”
METLIFE INC incurred senior notes of ¥7,100,000,000 aggregate principal amount of its 1.009% Senior Notes due 2029 with The Bank of New York Mellon Trust Company, N.A. at 1.009% maturing 2029.
“On March 7, 2024, MetLife, Inc. (the “Company”) issued ¥7,100,000,000 aggregate principal amount of its 1.009% Senior Notes due 2029 (the “2029 Senior Notes”)”
Laura J. Hay was elected as Director at METLIFE INC.
“On February 27, 2024, the Board of Directors (the “Board”) of MetLife, Inc. (the “Company”) elected Laura J. Hay a director of the Company and appointed Ms. Hay to its Audit Committee and its Finance and Risk Committee, effective immediately.”
METLIFE INC reported the quarter and full year ended December 31, 2023 results: net income Net income of $1.4 billion, compared to net income of $5.1 billion for the full year 2022, EPS Net income of $1.81 per share, down 71 percent from the prior year.
“On January 31, 2024, MetLife, Inc. issued (i) a news release announcing its results for the quarter and full year ended December 31, 2023 (the “Earnings Release”), a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.